

Health for all



GSK's mission is to improve the quality of human life by enabling people to do more, feel better, live longer. We are doing this by developing innovative products and improving access to healthcare for patients around the world.



This factsheet provides highlights from our 2013 Corporate Responsibility Report.

“Scientific and technological innovation will enable us to make the advances necessary to bring new medicines, in new ways, to patients everywhere. At GSK, we are working with many partners and across many areas – such as gene therapy and biopharmaceuticals – to develop medicines for diseases where effective treatments do not currently exist. We’re also playing our part in exploring new ways to stimulate innovation in areas where the commercial incentive is weaker – for example on TB, antibiotic resistance or Alzheimer’s”

Patrick Vallance
President, Pharmaceuticals R&D, GSK

6

Six significant new product approvals covering respiratory disease, cancer, HIV and flu.

Updated our tiered pricing model for vaccines.

Achieved a major milestone in the development of our malaria vaccine candidate.



Ground-breaking Partnership with Save the Children

In 2013 we announced a ground-breaking partnership with international children's charity, Save the Children, to help save the lives of one million children. By combining our expertise, resources and capabilities, we will bring much-needed medicines and vaccines to some of the world's poorest children, train thousands of healthcare workers, and seek to alleviate child malnutrition.

4bn

Donated our four billionth albendazole tablet to support efforts to eliminate lymphatic filariasis.

“Community health workers provide vital services to rural communities and GSK has been a pioneer and trail-blazer in supporting the deployment of CHWs across Africa. The One Million Community Health Workers Campaign will save lives and help rural communities in sub-Saharan Africa to break free of extreme poverty. By promoting the systematic deployment of a million CHWs, roughly 1 per 100 households in rural areas, the Campaign will support sub-Saharan Africa to make major strides towards the Millennium Development Goals and beyond.”

Jeffrey Sachs
Director of the Earth Institute and the Sustainable Development Solutions Network

Our commitments

In 2012, we developed 23 forward-looking commitments across the four areas of our responsible business approach. They aim to address unmet global health needs and are aligned with our strategic priorities and our values. We report our progress against these commitments in our 2013 Corporate Responsibility Report. The commitments for Health for all cover:

- Innovation for unmet medical needs
- Developing vaccines that don't need to be kept cold
- Building products to better meet needs
- Better access to medicines and vaccines
- Reducing child mortality
- Strengthening healthcare infrastructure
- Access to antiretroviral treatment for HIV
- Fighting malaria
- Eliminating and controlling neglected tropical diseases
- Eradicating polio

Innovative science to create value for all

£3.4bn

We are committed to creating innovative products that deliver value for all – healthcare payers and providers, and most of all, patients. In 2013 we invested £3.4 billion in global research and development for innovative medicines, vaccines and consumer products.

Exceptional R&D delivery

2013 was the most productive period of R&D output in the company's history.

We achieved six significant new product approvals covering respiratory disease, skin cancer, HIV and flu. GSK accounted for 19% of FDA new drug approvals during 2013.

Targeting unmet need

We adopt flexible business models to address areas of unmet medical need where there is not necessarily potential for commercial return. For example, we are working with others to encourage research into areas such as new antibiotics, Alzheimer's disease and antibiotic resistance.

Sharing our research

We believe that by sharing our research findings we can help accelerate drug development. We have shared our compound library for malaria and TB.

38 visiting scientists at Tres Cantos.

38 visiting scientists, focused on discovering and developing new medicines for diseases of the developing world, have made use of our Open Lab in Tres Cantos Spain.

Access to healthcare

We are committed to improving access to our products – irrespective of where people live or their ability to pay – by focusing on the affordability and availability of our products, and investing in strengthening health systems.

Affordability

In 2013 we updated our tiered pricing model for vaccines to increase support for countries committed to long-term immunisation programme that reflect their ability to pay.

89m

In Least Developed Countries we cap the prices of our patented medicines at no more than 25% of prices charged in developed countries. Since 2010 the volume of medicines we supply to these countries has increased by 60% to 89 million packs of product in 2013.

In middle-income countries we offer a range of payment schemes to help patients afford the treatments they need.

We also take a responsible approach to pricing in high income countries and have priced our newly launched products at or below the prices of those currently available, despite their positively differentiated profiles.

Making our products more available

Through our 'catch up' programme we received approvals in developing countries for a further 26 products treating non-communicable diseases, respiratory, antibiotics and oncology.

46.8m

We delivered 46.8 million vaccine doses to the GAVI Alliance at affordable prices to protect children from pneumococcal diseases, rotavirus gastroenteritis and cervical cancer.

Strengthening healthcare infrastructure

£5.1m

We reinvest 20% of profits we make in Least Developed Countries into training frontline community healthcare workers and improving access to healthcare in these countries. In 2013 this totalled £5.1 million.

Diseases of the developing world

More than one billion people, including 800 million children, are affected by Neglected Tropical Diseases (NTDs).

4bn albendazole tablets.

In 2013 we donated our 4 billionth albendazole tablet to support efforts to eliminate lymphatic filariasis. Our albendazole donation programme has reached over 600 million people – 200 million of whom are children – since it began in 2000.

Malaria

In 2013, we achieved a major milestone in the development of the world's first malaria vaccine. RTS,S, the most clinically advanced malaria vaccine candidate to date almost halved the number of malaria cases in young children (aged 5-17 months at first vaccination) and reduced by around a quarter the malaria cases in infants (aged 6-12 weeks at first vaccination) over 18 months. We have committed to price the vaccine at not-for-profit.

HIV/AIDS

ViiV Healthcare reached an important milestone with the FDA approval of Tivicay.

ViiV's first new treatment to be delivered, *Tivicay* (dolutegravir), is an investigational integrase inhibitor, which blocks an HIV enzyme (integrase) and prevents HIV from replicating for adults and children, 12 years and older, living with HIV.

Health and wellbeing in our communities

GSK supports the development of healthcare infrastructure and contributes to scientific education, as well as assisting humanitarian relief efforts.

£221m

In 2013, our global community investment totalled £221 million (\$347 million), compared with £206 million (\$330 million) in 2012.